39 F.4th 1377
Fed. Cir.2022Background
- Thales and Philips are telecom equipment makers; Philips alleges Thales implemented ETSI-defined SEPs and seeks FRAND licensing.
- After FRAND negotiations failed, Philips sued Thales in the District of Delaware and filed an ITC complaint seeking an exclusion order.
- Thales counterclaimed for breach of contract and a declaratory FRAND rate and moved for a preliminary injunction to bar Philips from pursuing the ITC action.
- The district court denied Thales’ preliminary injunction motion; Thales appealed to the Federal Circuit.
- The Federal Circuit reviewed for abuse of discretion and affirmed, holding Thales failed to show likely irreparable harm from the ITC proceedings because its evidence was speculative (customer “concerns” and a business “cloud”) and lacked concrete losses.
Issues
| Issue | Thales' Argument | Philips' Argument | Held |
|---|---|---|---|
| Whether Thales showed likely irreparable harm from Philips’ ITC action | Customer concern and a “cloud” over business from possible exclusion order will cause irreparable injury | Alleged harm is speculative; no evidence of lost customers, delayed purchases, or financial harm | No — evidence was conclusory/speculative; no likely irreparable harm shown |
| Whether the district court abused its discretion in denying the preliminary injunction | Injunction necessary to prevent irreparable harm and protect FRAND adjudication | Denial was within court’s discretion under applicable PI standards and record | No abuse of discretion; denial affirmed |
Key Cases Cited
- Metalcraft of Mayville, Inc. v. The Toro Co., 848 F.3d 1358 (Fed. Cir. 2017) (standard for reviewing injunction denials and patent-specific considerations)
- Luminara Worldwide, LLC v. Liown Elecs. Co., 814 F.3d 1343 (Fed. Cir. 2016) (preliminary-injunction factors)
- Winter v. Nat. Res. Def. Council, Inc., 555 U.S. 7 (2008) (party must show likely—not speculative—irreparable harm)
- Novo Nordisk of N. Am., Inc. v. Genentech, Inc., 77 F.3d 1364 (Fed. Cir. 1996) (abuse-of-discretion review standards)
- Ferring Pharms., Inc. v. Watson Pharms., Inc., 765 F.3d 205 (Fed. Cir. 2014) (speculative customer reactions insufficient for irreparable harm)
- Takeda Pharms. U.S.A., Inc. v. Mylan Pharms. Inc., 967 F.3d 1339 (Fed. Cir. 2020) (affirming need for concrete evidence of harm)
- Celsis In Vitro, Inc. v. CellzDirect, Inc., 664 F.3d 922 (Fed. Cir. 2012) (example of sufficient irreparable-harm proof via specific financial evidence)